アポリプロテインA-Iのレベルは,特にHFmrEFとHFpEFにおける慢性心不全患者の予後と関連している
XueChun He1, FaPeng Li2, Jian Zhang1
1Department of Cardiology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, People's Republic of China.
International journal of general medicine
|September 2, 2025
まとめ
低アポリプロテインA- I (ApoA- I) レベルは,慢性心不全患者における全因死亡率 (ACM) の増加を予測する. この関連性は,中程度の心不全 (HFmrEF) と保存されたエジェクション分数 (HFpEF) のサブタイプにおいて有意であった.
科学分野:
- 心臓病科
- バイオマーカー
- 予測
背景:
- 慢性心不全 (CHF) は,世界的に大きな健康問題となっています.
- 信頼性の高い予後マーカーを特定することは,CHF患者の管理に不可欠です.
- アポリポプロテインA- I (ApoA- I) は,高密度リポプロテイン (HDL) の重要な成分であり,逆コレステロール輸送に役割を果たします.
研究 の 目的:
- 慢性心不全 (CHF) の患者におけるアポリポプロテインA- I (ApoA- I) の予測値と予後的意義を調査する.
- 異なるCHFサブタイプにおけるApoA- Iレベルと全因死亡率 (ACM) の関連性を評価する.
主な方法:
- 4442人のCHF患者が平均22. 75ヶ月間追跡された.
- 患者は,ROC曲線分析に基づいて,低いおよび高いApoA- Iグループに分けられた.
- ACMのリスクを決定するために多変量コックス回帰分析を使用した.
主要な成果:
- 全体のCHFコホートでは,APOA- Iのレベルが低いことがACMのリスクの増加と有意に関連していた (HR=0. 702,P < 0. 001).
- この関連性は,中程度のエジェクション分数 (HFmrEF) (HR=0. 443,P < 0. 001) と保存されたエジェクション分数 (HFpEF) (HR=0. 704,P = 0. 010) を有する心不全患者において依然として有意であった.
- HFrEF (HR=0. 806, P=0. 194) による心不全の患者では,ApoA- I値とACMとの間に有意な関連性が見つかりませんでした.
結論:
- アポリポプロテインA- I濃度は,全原因の死亡率と有意に関連しています.
- ApoA- Iの予後値は,HFmrEFとHFpEFにおいて特に顕著である.
- ApoA- Iは,特定のCHF集団におけるリスク分層の重要なバイオマーカーとして機能する.
さらに関連する動画
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
9.4K
04:05Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
Published on: June 30, 2023
2.2K
関連する概念動画
01:30Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:27Heart Failure I: Introduction
52
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
52
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27